Clinical trials: Breast Imaging
Breast Cancer
Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Breast Cancer
The purpose of this study is to determine if new methods of MRI imaging can better measure participants' response to chemotherapy treatment.
- Trial name
- NCT03650803
- Testing
- 3D MR Fingerprinting scan
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer, Diagnostic Imaging
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI
The purpose of this study is to look at the efficacy (how does it work) and safety of gadobutrol when used for obtaining MR images of both breasts.Women with a recent diagnosis of breast cancer by mammogram (X-ray examination of…
- Trial name
- NCT01067976
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Where
- 40 sites in United States, Argentina and 7 more
- Volunteers
- 446 people
- Sponsor
- Bayer
Pain
Does Alkalinization Reduce Perceived Pain Levels During Sentinel Lymph Node Imaging?
Pain during nuclear medicine breast lymphnode detection procedures has been reported as high as 8.8/10. Using Sodium Bicarbonate to alkalinize the radio-pharmaceutical injection, pain can safely be reduced from 6.6/10 to 4.7/10…
- Trial name
- buffering SLN (NCT01660412)
- Testing
- Standard of Care First, ph Altered first
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Arkansas
Estrogen Receptor Positive, HER2/Neu Negative
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
This clinical trial studies fluorine F 18 fluorothymidine (FLT) positron emission tomography (PET) in measuring treatment response in patients with newly diagnosed estrogen receptor (ER)-positive, human epidermal growth factor…
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Stage IA Breast Cancer
- Trial name
- NCT01928186
- Testing
- Fluorothymidine F-18, Positron Emission Tomography, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Washington
Breast Cancer
Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts
We aim to compare the sensitivity of mammography to the sensitivity of Molecular Breast Imaging (a new gamma-camera based breast imaging technology) in women with dense breast tissue who are at increased risk for breast cancer.
- Trial name
- NCT00620373
- Testing
- Molecular Breast Imaging, Conventional Mammography, Technetium (99mTc) sestamibi
- Where
- United States
- Volunteers
- 969 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Breast Cancer
Quantitative Subharmonic Breast Imaging
This is a non-randomized trial of 450 women with a breast abnormality, who are scheduled for a breast biopsy of this abnormality. The study will be conducted at two clinical sites.
- Trial name
- NCT01490892
- Testing
- 3D HI and SHI of UCA
- Where
- 2 sites in United States
- Volunteers
- 219 people
- Sponsor
- Thomas Jefferson University
Breast Neoplasms
Study Assessing The Interest of Indocyanine Green Fluorescence Imaging With Radioisotope Method For Sentinel Lymph Node Biopsy in Patients With Breast Cancer
The sentinel node has a fundamental role in the management of early breast cancer. Currently, the double detection of blue and radioisotope is recommended.
- Trial name
- FLUOTECH (NCT02279108)
- Testing
- indocyanine green, isotope
- Where
- France
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Breast Cancer
Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer
The purpose of this study is to determine if Indocyanine Green (IC-GREEN) is comparable to isosulfan blue (IS-BLUE) in the identification of arm lymphatics and arm-draining nodes during nodal staging procedures in breast cancer.
- Trial name
- NCT01771666
- Testing
- SPY Elite Imaging, Indocyanine Green, Isosulfan blue
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Stanford University
Solid Tumors, High Grade Gliomas
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
Study aimed to assess the reproducibility of PET imaging using AH111585 (18F) Injection. Subjects are evaluable if they undergo 2 administrations of AH111585 (18F) Injection (3 to 8 days apart) and the corresponding PET…
- Conditions
- Solid Tumors, High Grade Gliomas, Lung Cancer, Head and Neck Cancer
- Trial name
- NCT00918281
- Testing
- Fluciclatide Injection
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- GE Healthcare
B-Cell Neoplasm, Estrogen Receptor Negative
18F-FSPG PET/CT for Cancer Patients on Therapy
The goal of this phase 2 study trial is to evaluate the utility of the radiolabel 18F-FSPG used before and after treatment to diagnose, predict, and evaluate response to therapy in patients with a wide variety of metastatic…
- Conditions
- B-Cell Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Renal Cell Cancer
- Trial name
- NCT02599194
- Testing
- 18F-FSPG, 18F-FDG
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Andrei Iagaru
Breast Cancer
The PIONEER-01 Study of the Imagio Breast Imaging System
This is a prospective controlled multi-center study involving gray scale (B-mode) ultrasound vs OA/US (opto-acoustic and gray scale ultrasound) for the visualization of suspicious masses.
- Trial name
- NCT01943916
- Testing
- Imagio OA/US (US and OA/US), Imagio gray scale ultrasound
- Where
- 16 sites in United States
- Volunteers
- 2,105 people
- Sponsor
- Seno Medical Instruments Inc.
Breast Carcinoma
Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer
This clinical trial studies positron emission tomography imaging in using copper Cu 64 TP3805in patients with breast cancer. Diagnostic procedures, such as positron emission tomography (PET) and positron emission mammography…
- Trial name
- NCT02810873
- Testing
- Positron Emission Mammography, Positron Emission Tomography, Fludeoxyglucose F-18
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Breast Cancer
DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy
RATIONALE: Imaging procedures, such as diffusion-weighted magnetic resonance imaging (DWI) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), may help in evaluating how well patients with breast cancer respond to…
- Trial name
- ACRIN6698 (NCT01564368)
- Testing
- diffusion-weighted magnetic resonance imaging
- Where
- 7 sites in United States
- Volunteers
- 406 people
- Sponsor
- American College of Radiology Imaging Network
Breast Cancer
Breast Cancer Detection: Comparison of Breast Tomosynthesis and Conventional Mammography
The primary hypothesis to be tested is: The detection of breast cancer will be increased with tomosynthesis (3D) imaging
- Trial name
- NCT01669148
- Testing
- Tomosynthesis, Conventional
- Where
- United States
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Breast Cancer
A Study to Evaluate the Accuracy of a Breast Cancer Locator (BCL) in Patients With Palpable Cancers
In this study, the investigators will enroll women with palpable cancers to assess the accuracy of the Breast Cancer Locator (BCL) and the concomitant procedure as a vehicle to optimize and validate the approach in such surgical…
- Trial name
- NCT02550210
- Testing
- Breast Cancer Locator (BCL)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Breast Cancer
Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer
To compare the kinetics and efficacy of two functionally different diagnostic agents, Lymphoseek (CD206 receptor targeted) and 99mTc-Sulfur Colloid (SC) (Sulfur Colloid non-specific mapping agent) in intraoperative lymphatic…
- Trial name
- Lymphoseek (NCT02287675)
- Testing
- Lymphoseek, Sulfur Colloid
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Kettering Health Network
Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
PET/CT or PET/MRI in Measuring Tumors in Patients Undergoing Clinical Imaging or With Newly Diagnosed Breast Cancer
This clinical trial studies positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) in measuring tumors in patients undergoing clinical imaging or with newly diagnosed breast cancer.
- Trial name
- NCT01892540
- Testing
- positron emission tomography/computed tomography, PET/MRI, Position Device
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer
Pilot Study to Evaluate High Resolution PET Image-Guidance for Sampling of Breast Abnormalities
The purpose of this pilot clinical study is to test a methodology for using high-resolution Positron Emission Tomography (PET) imaging to guide vacuum-assisted core biopsy of breast abnormalities identified on PET.
- Trial name
- PEM-BX (NCT00606931)
- Testing
- Stereo Navigator Accessory to PEM Flex PET Scanner
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Naviscan PET Systems
Breast Cancer, Head and Neck Squamous Cell Carcinoma
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
This study is to evaluate diagnostic performance, safety and timing of post-dose imaging of ONM-100, an intraoperative fluorescence imaging agent for the detection of cancer in patients with solid tumors undergoing routine…
- Conditions
- Breast Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT03735680
- Testing
- ONM-100
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- OncoNano Medicine, Inc.
Breast Cancer
Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer
Enrolled women will undergo a bilateral Contrast-Enhanced Breast Magnetic Resonance Imaging (CE-BMRI) as per usual clinical practice within 30 days of breast cancer diagnosis.
- Trial name
- NCT01303419
- Testing
- CE-BMRI, DE-CEDM
- Where
- 5 sites in United States, Belgium and 3 more
- Volunteers
- 224 people
- Sponsor
- GE Healthcare